Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700163 · ClinicalTrials.gov registry record · Phase 1
RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04700163 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 23 participants.
The verdict
NCT04700163, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, single dose, dose-escalation phase 1 study to evaluate the safety and pharmacokinetics of a combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein in healthy volunteers.
Interventions
- BIOLOGICAL C144-LS and C-135-LS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04700163
The ClinicalTrials.gov registry entry for NCT04700163 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which C144-LS and C-135-LS is the first listed.
NCT04700163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04700163 about?
NCT04700163 is a clinical study titled "RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers". This is a first-in-human, open label, single dose, dose-escalation phase 1 study to evaluate the safety and pharmacokinetics of a combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein i...
What is the current status of trial NCT04700163?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2021-01-11. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT04700163?
The interventions under investigation include: C144-LS and C-135-LS (BIOLOGICAL).
Who is sponsoring clinical trial NCT04700163?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.